The Importance of Body Weight for the Dose Response Relationship of Oral Vitamin D Supplementation and Serum 25-Hydroxyvitamin D in Healthy Volunteers by Ekwaru, John Paul et al.
 
The Importance of Body Weight for the Dose Response
Relationship of Oral Vitamin D Supplementation and Serum 25-
Hydroxyvitamin D in Healthy Volunteers
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ekwaru, John Paul, Jennifer D. Zwicker, Michael F. Holick,
Edward Giovannucci, and Paul J. Veugelers. 2014. “The
Importance of Body Weight for the Dose Response Relationship
of Oral Vitamin D Supplementation and Serum 25-
Hydroxyvitamin D in Healthy Volunteers.” PLoS ONE 9 (11):
e111265. doi:10.1371/journal.pone.0111265.
http://dx.doi.org/10.1371/journal.pone.0111265.
Published Version doi:10.1371/journal.pone.0111265
Accessed February 17, 2015 5:41:45 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454666
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe Importance of Body Weight for the Dose Response
Relationship of Oral Vitamin D Supplementation and
Serum 25-Hydroxyvitamin D in Healthy Volunteers
John Paul Ekwaru
1, Jennifer D. Zwicker
2, Michael F. Holick
3, Edward Giovannucci
4, Paul J. Veugelers
1*
1School of Public Health, University of Alberta, Edmonton, Alberta, Canada, 2School of Public Policy, University of Calgary, Calgary, Alberta, Canada, 3Section of
Endocrinology, Nutrition and Diabetes, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 4Harvard School
of Public Health, Departments of Nutrition and Epidemiology, Boston, Massachusetts, United States of America
Abstract
Unlike vitamin D recommendations by the Institute of Medicine, the Clinical Practice Guidelines by the Endocrine Society
acknowledge body weight differentials and recommend obese subjects be given two to three times more vitamin D to
satisfy their body’s vitamin D requirement. However, the Endocrine Society also acknowledges that there are no good
studies that clearly justify this. In this study we examined the combined effect of vitamin D supplementation and body
weight on serum 25-hydroxyvitamin (25(OH)D) and serum calcium in healthy volunteers. We analyzed 22,214 recordings of
vitamin D supplement use and serum 25(OH)D from 17,614 healthy adult volunteers participating in a preventive health
program. This program encourages the use of vitamin D supplementation and monitors its use and serum 25(OH)D and
serum calcium levels. Participants reported vitamin D supplementation ranging from 0 to 55,000 IU per day and had serum
25(OH)D levels ranging from 10.1 to 394 nmol/L. The dose response relationship between vitamin D supplementation and
serum 25(OH)D followed an exponential curve. On average, serum 25(OH)D increased by 12.0 nmol/L per 1,000 IU in the
supplementation interval of 0 to 1,000 IU per day and by 1.1 nmol/L per 1,000 IU in the supplementation interval of 15,000
to 20,000 IU per day. BMI, relative to absolute body weight, was found to be the better determinant of 25(OH)D. Relative to
normal weight subjects, obese and overweight participants had serum 25(OH)D that were on average 19.8 nmol/L and
8.0 nmol/L lower, respectively (P,0.001). We did not observe any increase in the risk for hypercalcemia with increasing
vitamin D supplementation. We recommend vitamin D supplementation be 2 to 3 times higher for obese subjects and 1.5
times higher for overweight subjects relative to normal weight subjects. This observational study provides body weight
specific recommendations to achieve 25(OH)D targets.
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Introduction
Vitamin D has been shown to benefit bone health, to prevent
rickets, osteomalacia and symptomatic hypocalcaemia, and to
reduce the burden of other specific diseases [1–5]. To reduce
burden of disease, various institutions recommend defined
amounts of vitamin D intake [6–8]. The established proxy for
vitamin D status, however, is serum 25-hydroxyvitamin D
(25(OH)D) [9,10]. This proxy has been used for definitions of
vitamin D deficiency (for example, serum 25(OH)D levels below
50 nmol/L), vitamin D insufficiency (serum 25(OH)D levels
between 50 and 75 nmol/L), and vitamin D toxicity (serum
25(OH)D levels exceeding 500 nmol/L) [7], though these
definitions are not established. With recommendations based on
vitamin D intake and serum 25(OH)D as the best proxy for
nutritional status, a good quantification of the dose response
relationship between vitamin D intake and serum 25(OH)D is
essential. However, this dose response relationship is currently not
well documented, particularly not for a wider range and including
high levels of vitamin D supplementation.
The Recommended Dietary Allowance (RDA) is the nutrient
intake considered to be sufficient to meet the requirements of
97.5% of healthy individuals. The RDA for vitamin D, 600 IU
day for individuals 1 to 70 years of age and 800 IU per day for
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e111265those above the age of 70 years [8]. Although differences in serum
25(OH)D by body mass index (BMI) and by absolute body weight
have been reported [11–19], the RDA does not consider either.
The Clinical Practice Guidelines by the Endocrine Society do
acknowledge body weight differentials and recommended obese
subjects be given two to three times more vitamin D to satisfy their
body’s vitamin D requirement, however they acknowledge that
there are no studies that clearly justify this [7,20].
The objectives of the present study are to characterize the dose
response relationship of oral vitamin D supplementation and
serum 25(OH)D in a large sample of healthy volunteers, and to
quantify the extent this dose response relationship is different for
BMI and for absolute body weight. As the effect of vitamin D on
serum calcium and the risk for hypercalcemia is the most common
argument against high doses of vitamin D supplementation, we
further studied the relationship between vitamin D supplementa-
tion and calcium homeostasis.
Methods
This study is based on information from healthy volunteers
participating in a preventive health program provided by the Pure
North S’Energy Foundation (PN), a not-for-profit charitable
organization providing free services since October 2007. The
program and data collection protocol are described elsewhere
[21,22]. In brief, PN offers health promotion counseling with an
emphasis on vitamin D supplementation as their volunteers mostly
reside in the Canadian province of Alberta which is located
between the 49
th and 60
th parallel north. PN asks participants to
complete a lifestyle questionnaire, have their height and weight
measured, have a medical history, and have blood drawn for the
assessment of serum 25(OH)D. Since January 2009 the medical
history recorded the question ‘how much vitamin D supplemen-
tation are you using?’ This includes vitamin D from vitamin D
supplementation and from multivitamins. Also calcium supple-
mentation was recorded in the medical history. All 22,214 per
protocol study visits, that are typically scheduled once a year, prior
to June 2013 were included in the present study. All 25(OH)D
measurements were assessed with an automated chemiluminescent
immunoassay from DiaSorin (LIAISON) which measures the
combination of D2 and D3 and which has coefficients of variation
ranging from 6.8% to 8.8%.
Various shapes of the relationship between vitamin D intake
and 25(OH)D have been proposed [11,23–26]. These include
linear, polynominal, bi-phasic, exponential and ‘exponential plus
linear’ relationships [11,23-26]. We therefore sought to identify
the regression model that best characterized the relationship by
comparing linear, quadratic, cubic, linear-log, exponential and
‘exponential plus linear’ regression models on the basis of the
Akaike Information Criteria (AIC) [27].
We examined the importance of both BMI and absolute body
weight for the dose response relationship of oral vitamin D
Table 1. Summary of 22,214 simultaneous assessments of oral vitamin D supplementation and serum 25(OH)D level.
N % Mean Std
Vitamin D supplementation (IU per day) 22214 2841.6 4022.5
Serum 25(OH)D level nmol/L 22214 90.5 46.5
Albumin corrected calcium (mmol/L) 10940 2.4 0.1
Age (Years)
,40 7800 35.1
40 to 49 4766 21.5
50 to 59 5291 23.8
60+ 4357 19.6
Gender
Female 10944 49.3
Male 11270 50.7
Weight Status
Underweight 279 1.3
Normal weight 7197 33.4
Overweight 7962 36.9
Obesity 6131 28.4
Absolute weight
,60 kg 2270 10.6
60 kg to 80 kg 8734 40.8
80.1 to 100 kg 7232 33.8
.100 kg 3158 14.8
season
Winter 7320 33.0
Spring 7039 31.7
Summer 4294 19.3
Fall 3561 16.0
doi:10.1371/journal.pone.0111265.t001
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confounding potential of age, sex and season using multivariable
regression models. We compared BMI and absolute body weight
both as continuous and categorical variables. When categorized,
individuals with a BMI of less or equal than 18.5, more than 18.5
and less or equal than 25, more than 25 and less or equal than 30,
and more than 30 were considered underweight, normal weight,
overweight and obese, respectively [28]. Weight was categorized
as less than 60 kg, 60 kg to 80 kg, more than 80 kg and less or
equal to 100 kg, and more than 100 kg.
Assessments of height and weight were missing in 3% of the
assessments. These records were excluded in analyses with BMI
and absolute body weight as continuous covariates, but were
included in analyses with BMI and absolute body weight as
categorical covariates by considering missing values as a missing
category. Differences in the dose response relationship of oral
vitamin D supplementation and serum 25(OH)D by BMI were
visualized through plots of model estimated 25(OH)D levels for
any given supplementation levels.
As the available data included repeated observations for a subset
of 3416 (19.4%) subjects, we included a random intercept in all the
exponential regression models. The effects of vitamin D supple-
mentation on calcium levels and probability of hypercalcemia
were analyzed using linear regression and logistic regression,
respectively.
All analyses were conducted using SAS 9.4 (SAS Institute, Cary
NC) and the dose response curves were fitted using PROC
NLMIXED, a SAS procedure for fitting nonlinear mixed effect
models. Statistical significance was defined as p-values less than
0.05.
PN anonymized their data prior to forwarding it to the
University of Alberta for analyses. The Human Research Ethics
Board of the University of Alberta had approved access to and
analysis of the PN data for the purpose of the present analyses.
Results
Participants reported vitamin D supplementation ranging from
0 to 55,000 IU per day. Sixty-nine participants (0.3%) reported
supplementation above 20,000 IU per day. The participants had
serum 25(OH)D levels ranging from 10.1 to 394 nmol/L. Of all
participants, 33.4% were normal weight, 1.3% underweight,
36.9% overweight and 28.4% obese (Table 1).
Table 2 depicts characteristics of the linear, quadratic, cubic,
linear-log, exponential and ‘exponential plus linear’ regression
models that describe the dose response relationship between oral
vitamin D supplementation and serum 25(OH)D. The exponential
regression model appeared to describe the dose response
relationship best. This conclusion is based on the observation that
the AIC for the exponential regression model was lower than for of
the other regression models (Table 2).
The dose response relationship between vitamin D supplemen-
tation and serum 25(OH)D for supplementation levels of
20,000 IU per day or less is depicted in Figure 1. Bubbles
represent the mean serum 25(OH)D level for all reported doses of
vitamin D supplementation. The size of the bubbles is propor-
tional to the number of assessments for each of the doses. Though
the entire range of supplementation values was included in
Figure 1. The dose response relationship between oral vitamin D supplementation and serum 25(OH)D levels based on 22,214
observations of healthy volunteers. Footnote: Bubbles represent the mean plasma 25(OH)D level for all reported daily doses. The size of the
bubbles is proportional to the number of assessments for each of the reported daily doses. The red line represents the fitted dose response curve.
doi:10.1371/journal.pone.0111265.g001
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PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e111265analyses, the graphs are plotted up to 20,000 IU. The red line
represents the fitted exponential dose response curve and confirms
the clear impression from the bubbles that the dose response
relationship is non-linear and levels off at increasingly higher
supplementation levels. The parameter Y0, that represents the
average serum 25(OH)D level reached without vitamin D
supplementation, was estimated to be 68.0 nmol/L (95% CI:
67.3, 68.7).
For Figure 2 we restricted our analyses to those subjects that
had both their baseline visit and a follow up visit between January
2009 and June 2013 and had reported not to supplement with
vitamin D at their baseline visit (1205 subjects, 2410 assessments).
This analysis mimics a pre-post comparison of an intervention: a
comparison of observations prior to introduction to vitamin D
supplementation with observations, on average, 0.98 years after
the baseline visit. As such, the blue bubbles in figure 2 represent
the expected 25(OH)D level of participants who have been taken
oral doses of vitamin D for an average of 0.98 year since baseline.
The blue line represents the fitted dose response curve for this
subset of 1205 subjects. The red line is identical to the red line in
Figure 1 representing the fitted dose response curve for the
complete sample (22,214 assessments from 17,614 subjects). The
red line in Figure 2 (and the observations presented in Figure 1)
could be described as a ‘snapshot of an ongoing intervention
program’. The fact that the red and blue lines in Figure 2 are
similar illustrates that a ‘pre-post comparison’ and a ‘snapshot of
an ongoing intervention program’ reveal similar results.
Both Figure 1 and 2 show that the increase in serum 25(OH)D
is leveling off at higher doses of vitamin D supplementation. Serum
25(OH)D levels are estimated to increase on average by
11.98 nmol/L per 1,000 IU in the supplementation interval of 0
to 1,000 IU per day and by 1.13 nmol/L per 1,000 IU in the
supplementation of 15,000 to 20,000 IU per day. In addition to
supplementation, also age, BMI, absolute body weight, gender and
season are associated with serum 25(OH)D levels in a statistically
significant manner (Table 3). The differences across BMI catego-
ries (Table 3, column 1) are pronounced: obese subjects and
overweight subjects had serum 25(OH)D levels that were on
average 19.8 nmol/L lower and 8.0 nmol/L lower than those of
normal weight subjects, respectively. The differences in serum
25(OH)D levels between underweight and normal weight subjects
were not statistically significant. Differences across absolute weight
categories were also substantial and statistically significant
(Table 3, column 2). In table 3, the AIC values were smaller in
models that included BMI relative to models that included
absolute body weight regardless of whether they were considered
as categorical (213710.6 versus 213990.2; Table 3: columns 1 and
2) or continuous (213602.0 versus 213852.0; Table 3, columns 1
and 2) covariates, suggesting BMI to be a better predictor of
25(OH)D relative to absolute weight. When considering BMI and
absolute weight simultaneously (Table 3: columns 3 and 6), BMI
appeared to be the better proximate determinant of 25(OH)D.
This conclusion is based on the observation that the estimated
coefficients for BMI changed only slightly when absolute weight is
included in the model (column 3 versus column 1 and column 6
versus column 4), while the coefficients for absolute weight
changed substantially when BMI is included (Table 3, column 3
versus 2 and column 6 versus 5).
Figure 2. The relationship between oral vitamin D supplementation dose and serum 25(OH)D level at the follow up visits of a
subgroup of 1205 healthy volunteers who reportedly did not supplement at their baseline visit. Footnote: Bubbles represent the mean
plasma 25(OH)D level for all reported daily doses. The size of the bubbles is proportional to the number of assessments for each of the reported daily
doses. The blue line represents the fitted relationship for the subgroup of participants who reportedly did not supplement at their baseline visit. The
red line represents the fitted relationship of the entire sample (22,214 observations). Both analytic approaches revealed similar dose response
relationships as the red and blue lines are similar.
doi:10.1371/journal.pone.0111265.g002
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PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e111265The BMI differences in the dose response relationship are
further visualized in Figure 3. Relative to normal weight subjects,
obese subjects had lower 25(OH)D values and curved differently.
Serum 25(OH)D was estimated to increase at an average rate of
13.1 nmol/L per 1000 IU, 11.5 nmol/L per 1000 IU and
8.6 nmol/L per 1000 IU among normal weight, overweight and
obese participant, respectively in the supplementation interval of 0
to 1000 IU per day. The average rates of increase then reduce to
1.3 nmol/L per 1000 IU, 1.5 nmol/L per 1000 IU and
1.9 nmol/L per 1000 IU, respectively in the supplementation
interval of 15,000 IU to 20,000 IU per day.
Table 4 provides estimates for the relationship of supplemen-
tation and serum 25(OH)D by BMI category. Supplementation
with 600 IU per day would achieve average serum 25(OH)D levels
of 83, 76 and 66 nmol/L for normal weight, overweight and obese
participants, respectively (Table 4). Average serum 25(OH)D
levels of 100 nmol/L in normal weight, overweight and obese
subgroups, are estimated to require supplementation with
2,080 IU, 3,065 IU and 5,473 IU per day, respectively (Table 4).
Relative to normal weight participants, this represents a 1.47 and
2.6 times higher dose for overweight and obese subjects,
respectively.
For the 10,940 visits that included assessments for serum
calcium, the mean albumin corrected calcium level was
2.35 mmol/L (standard deviation=0.11) and ranged from 1.79
to 3.23. Figure 4 shows the dose response relationship between
vitamin D supplementation and serum calcium levels. In a linear
regression model that adjust for age, BMI, gender, season, and
calcium supplementation, serum calcium levels did not increase
significantly by increasing daily vitamin D supplementation:
0.001 mmol/L per 1000 IU increase in daily vitamin D supple-
mentation, p-value=0.165 (Table 5).
Of the 10,940 visits that included assessments of serum calcium,
189 (1.7%) had albumin corrected calcium levels exceeding
2.6 mmol/L (hypercalcemia). In a logistic regression model that
adjusted for age, BMI, gender, season, and calcium supplemen-
tation, there was no statistically significant effect of vitamin D
supplementation on the probability of having hypercalcemia
(Table 5: Odds ratio=0.97 per 1000 IU increase in daily vitamin
D supplementation, p-value=0.286). Also, the probability of
having hypercalcemia was not statistical significantly different for
overweight and obese subjects relative to normal weight subjects.
In contrast, female gender and older age appeared important risk
factors for hypercalcemia (Table 5).
Discussion
We observed substantial differences in serum 25(OH)D across
categories of BMI and absolute body weight, which concurs with
observations by others [11–19] and deviates from reports that
concluded an absence of body weight differentials [29,30]). The
present study suggests that, on statistical grounds, BMI is the better
measure relative to absolute body weight to determine which
vitamin D doses are needed for which body weight groups to
achieve specific serum 25(OH)D targets. The present study also
adds to the existing knowledge by revealing that the magnitude of
the differences in serum 25(OH)D between normal weight and
obese subjects varies by supplementation dose. Furthermore, this
study provides detailed recommendations for supplementation to
achieve 25(OH)D targets specific for normal weight, overweight
Figure 3. The dose response relationship between oral vitamin D supplementation and plasma 25(OH)D levels by body mass index
category. Footnote: the lines are estimated using an exponential plus linear regression model that adjusted for age, gender, and season.
doi:10.1371/journal.pone.0111265.g003
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PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e111265and obese individuals (provided in Table 4). These recommenda-
tions appeared 2 to 3 times higher for obese participants relative to
normal weight subjects, depending on the 25(OH)D target level.
This is consistent with the Endocrine Society’s recommendation
that obese subjects be given two to three times more vitamin D
[7,20]. Estimates for overweight individuals appeared approxi-
mately 1.5 times higher relative to normal weight subjects. The
number of underweight participants was relatively small though do
suggest underweight subjects need less vitamin D supplementation
relative to normal weight subjects. Others had reported an absence
of differences between underweight and normal weight subjects
[31]. This study recommends guidelines for vitamin D supple-
mentation be specific for normal weight, overweight and obese
individuals, but this study does not recommend specific supple-
mentation levels or specific 25(OH)D target levels.
We observed an exponential dose response relationship
whereby serum 25(OH)D levels off with increasing levels of oral
vitamin D supplementation. On average, serum 25(OH)D was
estimated to increase by approximately 12.0 nmol/L per 1,000 IU
in the supplementation interval 0 to 1,000 IU per day and by
1.1 nmol/L per 1,000 IU in the supplementation interval of
15,000 to 20,000 IU per day. Other studies reported that an
additional 1,000 IU of vitamin D could increase serum 25(OH)D
by approximately 20 to 25 nmol/L [24,32]. The substantial
differences may arise from their focus on subjects with low baseline
serum 25(OH)D levels, whereas our study had enrolled healthy
volunteers. Also Garland et al. [23] and Aloia et al. [11] had
reported dose response relationships that leveled off. Garland et al.
[23] modeled cross sectional observations of 3,667 US based
community volunteers and Aloia et al. [11] plotted aggregated
outcomes of 62 controlled trials. The increase in serum levels per
unit increase in supplementation varied across the three studies as
a result of, at least in part, differences in study population
characteristics. Participants of the present study resided at, on
average, a latitude of 53 degrees [21] and had presumably less
subcutaneous production of vitamin D by sun exposure. Partic-
ipants of the present study reportedly without supplemental
vitamin D had an average serum level of 68 nmol/L, which
approximates the Canadian average of 67.7 nmol/L [33].
Luxwolda et al [34] reported serum 25(OH)D levels ranging from
58 to 171 nmol/L (average 115 nmol/L with 90% having serum
25(OH)D of less than 150 nmol/L) for traditional living popula-
tions in East Africa and suggested that this may represent ‘natural
levels’. The present study shows that on average the upper limit of
171 nmol/L was not reached with oral supplementation of
20,000 IU per day.
The IOM report states that vitamin D toxicity is rare at
10,000 IU per day but more common with regular doses of
50,000 IU per day, suggesting the toxicity range likely starts at
500 nmol/L [8]. In the present study where substantial numbers
of participants reported up to 20,000 IU of vitamin D per day, and
some even more, the highest serum 25(OH)D value observed was
394 nmol/L. This seems consistent with safety studies that
reported an absence of adverse effects from vitamin D doses of
up to 50,000 IU per day [35,36]. Our observation that
supplementation dose was not associated with hypercalcemia in
a statistically significant manner is consistent with an earlier report
Figure 4. The dose response relationship between vitamin D supplementation and calcium levels. Footnote: Bubbles represent the
mean serum calcium level for all reported daily doses. The size of the bubbles is proportional to the number of assessments for each of the reported
daily doses. The linear regression line is adjusted for age, gender, BMI, season and calcium supplementation.
doi:10.1371/journal.pone.0111265.g004
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PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e111265that daily doses of up to 40,000 IU per day are not associated with
hypercalcemia [37].
This study represents the first body weight specific character-
ization of the dose response relationship of a wide range of vitamin
D supplementation and serum 25(OH)D levels. The strengths of
the study include the large population, the relatively high
supplementation dose, and the fact that all serum samples were
subjected to the same 25(OH)D assessment methods, with heights
and weights measured rather that self-reported. The questions
regarding vitamin D supplementation by health professionals
may have introduced recall bias and social desirability bias.
Information on the duration of using vitamin D supplementation
had not been collected. Where participants changed their doses in
the months prior to the 25(OH)D assessment, this also may have
introduced error. However, we expect the latter error to be small
as all participants are aware that the objective of the 25(OH)D
assessment is to receive advice on vitamin D supplementation
dose, and therefore not likely to changing their supplementation
dose in the months prior to the assessment. Although this study
included residents of Northern latitude where sun exposure and
subcutaneous synthesis of vitamin D are considered limited, and
despite our adjustment for season as a proxy of sun exposure, we
acknowledge that a precise measure of daily hours of sun exposure
may have yielded better estimates. Likewise, where we did adjust
for the confounding potential of age, gender, and season, we
acknowledge that further adjustment for skin color, physical
activity, outdoor activities and dietary intake may have yielded
better estimates. Unlike in blinded trials, confounding by
indication, whereby participants whose 25(OH)D levels respond
well to vitamin D may lower their dose and participants whose
25(OH)D levels do not respond well may increase their dose, may
have biased the estimates of the present study. Lastly, we
recommend large randomized controlled trails among healthy
subjects be analyzed on BMI differentials in the dose response
relationship between vitamin D intake and serum 25(OH)D to
confirm the present findings.
In summary, we recommend clinical guidelines for vitamin D
supplementation be specific for normal weight, overweight and
obese individuals. In this study we provide body weight specific
recommendations to reach certain serum 25(OH)D target levels.
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Table 5. Determinants of serum calcium and hypercalcemia based on 10,940 assessments from healthy volunteers.
Serum calcium level Hypercalcemia
b (95%CI) p-value OR (95%CI) p-value
Vitamin D daily dose (per 1000 IU) 0.001(-0.000,0.001) 0.165 0.97(0.91,1.03) 0.286
Calcium supplementation (per 100 mg) 0.003(0.001,0.006) 0.015 1.20(1.03,1.39) 0.023
Age (Years)
,40 ref. ref.
40 to 49 0.003(20.003,0.009) 0.302 2.09(1.09,4.00) 0.026
50 to 59 0.029(0.023,0.035) ,.001 3.20(1.80,5.67) ,.001
60+ 0.044(0.038,0.050) ,.001 5.73(3.32,9.87) ,.001
Gender
Male 20.019(20.024, 20.015) ,.001 0.56(0.39,0.80) 0.001
Female ref. ref.
Weight Status
Underweight 20.005(20.026,0.015) 0.609 1.16(0.28,4.82) 0.837
Normal weight ref. ref.
Overweight 20.003(20.009,0.002) 0.239 1.05(0.69,1.59) 0.834
Obesity 0.008(0.002,0.013) 0.009 1.27(0.83,1.93) 0.267
Season
Spring 20.024(20.031, 20.016) ,.001 0.92(0.58,1.47) 0.728
Summer 20.017(20.022, 20.011) ,.001 0.57(0.34,0.96) 0.034
Fall 20.021(20.027, 20.015) ,.001 0.91(0.59,1.42) 0.682
Winter ref. ref.
Footnote: b: b-coefficient; OR: odds ratio; 95% CI: 95% confidence Interval; ref: reference category; all estimates are adjusted for age, gender, BMI category, season, and
supplementation with vitamin D and calcium.
doi:10.1371/journal.pone.0111265.t005
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